Miscellaneous KMO inhibitors have been developed and investigated for neurodegenerative disorders (33), for instance, a KMO tight-binding inhibitor, UPF 648, which is able to cross the blood–brain barrier in targeted therapies against neurodegenerative diseases (34). The gene discussed is KMO; the disease is neurodegenerative disease.